The association between expression of p53 and aggressiveness of serous adenocarcinoma of the uterine cervix
Sul Lee1, Hyun Joo Lee1, Kyung Un Choi2, Byung Su Kwon1, Dong Soo Suh1, Dae Hoon Jeong3, Geun Joo Kim4, Tae Hwa Lee4, Hyun-Jin Roh5, Ki Hyung Kim1
1 Department of Obstetrics and Gynecology, School of Medicine; Biomedical Research Institute, Pusan National University Hospital, Busan, South Korea 2 Biomedical Research Institute; Department of Pathology, School of Medicine, Pusan National University, Busan, South Korea 3 Department of Obstetrics and Gynecology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea 4 Department of Obstetrics and Gynecology, College of Medicine, Kosin University Gospel Hospital, Kosin University, Busan, South Korea 5 Department of Obstetrics and Gynecology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea
Correspondence Address:
Dr. Ki Hyung Kim Department of Obstetrics and Gynecology, School of Medicine, Pusan National University, 179, Gudeok-Ro, Seo-Gu, Busan 49241 South Korea
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jrms.JRMS_788_19
|
Background: Serous adenocarcinoma of the uterine cervix is an extremely rare variant of cervical adenocarcinoma. This study aimed to evaluate the clinicopathological and molecular features and outcomes of serous adenocarcinoma of the uterine cervix (SACC). Materials and Methods: This was a retrospective study conducted based on the clinical and pathological data of seven patients diagnosed with SACC after hysterectomy, who were evaluated at the gynecologic oncologic centers between 2010 and 2019. Results: Five cases were diagnosed at Stage IB and two at Stage IV. All patients underwent radical hysterectomy with bilateral salpingo-oophorectomy and subsequently received postoperative radiotherapy or chemotherapy. One patient showed persistent disease, and two patients suffered recurrence. Immunohistochemical study showed that three (43%) of the seven patients were positive for p53, and among these three patients, two with diffuse strong p53 expression experienced an aggressive course with recurrences at pelvic lymph nodes, lung, and brain. Conclusion: High p53 expression and advanced stage may be associated with poorer clinical outcomes in SACC, which suggest that immunohistochemistry may contribute to the prediction of prognosis.
|